Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gamgertamig - KeyMed Biosciences

Next Previous
Drug Profile

Gamgertamig - KeyMed Biosciences

Alternative Names: CM-336; OM-336

Latest Information Update: 20 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KeyMed Biosciences
  • Developer KeyMed Biosciences; Ouro Medicines
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Autoimmune haemolytic anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyloidosis
  • Phase I/II Bullous pemphigoid; Cytopenia; Haemolytic anaemia; Idiopathic thrombocytopenic purpura; Multiple myeloma
  • Phase I Myositis; Sjogren's syndrome
  • Clinical Phase Unknown Autoimmune haemolytic anaemia

Most Recent Events

  • 13 Feb 2026 Institute of Hematology & Blood Diseases Hospital plans to initiate a phase II CAREMM-007 trial for Multiple Myeloma (Newly diagnosed) (SC) (NCT07409454)
  • 12 Feb 2026 Institute of Hematology & Blood Diseases Hospital plans a phase I trial in Multiple myeloma (Second-line therapy or greater) in June 2026 (Parenteral, Infusion) (NCT07407010)
  • 20 Jan 2026 Gamgertamig receives Fast track status from the US FDA for Autoimmune hemolytic anemia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top